Publications by authors named "Alan Charney"

Claim this Profile
R
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Hong Zhang, Dana V Rizk, Vlado Perkovic, Bart Maes, Naoki Kashihara, Alan Charney

Kidney Int· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
David Kavanagh, Larry A Greenbaum, Arvind Bagga, Rajeshri G Karki, Chien-Wei Chen, Alan Charney

Kidney Int Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Dana V Rizk, Brad H Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Alan Charney

Kidney Int Rep· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting clinical and laboratory tests: importance and implications of context.
Alan N Charney, Jordan T Dourmashkin

Diagnosis (Berl)· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.
Patrick Rossignol, Rajiv Agarwal, Bernard Canaud, Alan Charney, Gilles Chatellier

Eur Heart J· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.
Michele Senni, John J V McMurray, Rolf Wachter, Hugh F McIntyre, Inder S Anand, Alan Charney

Eur J Heart Fail· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.
Michele Senni, John J V McMurray, Rolf Wachter, Hugh F McIntyre, Antonio Reyes, Alan Charney

Eur J Heart Fail· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
Sadayoshi Ito, Minoru Satoh, Yuko Tamaki, Hiromi Gotou, Alan Charney

Hypertens Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren.
Matthew R Weir, Anthony M Yadao, Das Purkayastha, Alan N Charney

J Cardiovasc Pharmacol Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Thomas E Delea, Oleg Sofrygin, James L Palmer, Helen Lau, Veronica C Munk, Alan Charney

J Am Soc Nephrol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The renin rise with aliskiren: it's simply stoichiometry.
A H Jan Danser, Alan Charney, David L Feldman, Juerg Nussberger, Naomi Fisher

Hypertension· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transition from acute to chronic hypercapnia in patients with periodic breathing: predictions from a computer model.
Robert G Norman, Roberta M Goldring, Jeremy M Clain, Beno W Oppenheimer, Alan N Charney

J Appl Physiol (1985)· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acid-base effects on intestinal Cl- absorption and vesicular trafficking.
Alan N Charney, Richard W Egnor, David Henner, Haroon Rashid, Nicholas Cassai

Am J Physiol Cell Physiol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of secretagogues and pH on intestinal transport in guanylin-deficient mice.
Alan N Charney, Richard W Egnor, Kris A Steinbrecher, Mitchell B Cohen

Biochim Biophys Acta· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-catalytic role of carbonic anhydrase in rat intestinal absorption.
Alan N Charney, Jesline Alexander-Chacko, Ramanashree Gummaconda, Richard W Egnor

Biochim Biophys Acta· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acid-base effects on intestinal Na(+) absorption and vesicular trafficking.
Alan N Charney, Richard W Egnor, Jesline Alexander-Chacko, Nicholas Cassai, Gurdip S Sidhu

Am J Physiol Cell Physiol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carbon dioxide affects rat colonic Na+ absorption by modulating vesicular traffic.
Alan N Charney, Richard W Egnor, Nicholas Cassai, Gurdip S Sidhu

Gastroenterology· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis